Skip to main content
. 2016 Dec 3;14:336. doi: 10.1186/s12967-016-1081-8

Table 2.

Association of thyroid hormone levels with incident CKD

Case/number (%) Model 1 Model 2 Model 3
Serum FT4
 Tertile 1 47/699 (6.7) 1.00 1.00 1.00
 Tertile 2 60/701 (8.6) 1.28 (0.86–1.91) 1.26 (0.83–1.91) 1.24 (0.82–1.88)
 Tertile 3 91/703 (12.9) 1.97 (1.36–2.86) 1.91 (1.30–2.81) 1.88 (1.27–2.77)
 P for trend <0.0001 0.0003 0.0008 0.001
 Each 1-pmol/l increase in FT4 198/2103 (9.4) 1.13 (1.05–1.21) 1.12 (1.04–1.20) 1.12 (1.05–1.20)
Serum FT3
 Tertile 1 65/687 (9.5) 1.00 1.00 1.00
 Tertile 2 68/712 (9.6) 1.07 (0.74–1.53) 1.11 (0.76–1.62) 1.12 (0.76–1.63)
 Tertile 3 65/704 (9.2) 1.09 (0.75–1.59) 1.06 (0.72–1.57) 1.04 (0.70–1.54)
 P for trend 0.88 0.64 0.76 0.86
 Each 1-pmol/l increase in FT3 198/2103 (9.4) 1.23 (1.01–1.49) 1.21 (0.99–1.49) 1.20 (0.98–1.47)
Serum TSH
 Tertile 1 64/700 (9.1) 1.00 1.00 1.00
 Tertile 2 74/700 (10.6) 1.13 (0.79–1.61) 1.31 (0.90–1.90) 1.34 (0.92–1.94)
 Tertile 3 60/703 (8.5) 0.86 (0.59–1.26) 0.99 (0.66–1.47) 1.04 (0.69–1.56)
 P for trend 0.70 0.45 0.99 0.80
 Each 1-μIU/ml increase in TSH 198/2103 (9.4) 0.99 (0.91–1.07) 0.99 (0.92–1.07) 1.00 (0.94–1.07)

Model 1: adjusted for age, sex, BMI at baseline

Model 2: further adjusted for triglyceride, HDL-c, diabetes and hypertension status, current smoking and drinking status, use of antihypertensive drugs, use of antidiabetic drugs, urinary ACR, eGFR at baseline

Model 3: further adjusted for TPOAb, TGAb at baseline

P for trend values for percentages of incident CKD are calculated by using Cochran–Mantel–Haenszel (CMH) method

Data are odds ratios (95% confidence intervals)

ACR albumin-to-creatinine ratio, BMI body mass index, CKD chronic kidney disease, eGFR estimated glomerular filtration rate, FT3 free triiodothyronine, FT4 free thyroxine, HDL-c high-density lipoprotein cholesterol, TSH thyroid-stimulating hormone, TPOAb thyroid peroxidase antibody, TGAb thyroglobulin antibody